iCAD Inc has announced that data produced using its Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) were presented at ASTRO.
The data show that at three years post-treatment, patients who had high dose rate (HDR) electronic brachytherapy with the Xoft System had good cosmesis, low toxicity levels, and no recurrences.
To date, more than 2,000 NMSC patients have been successfully treated with the Xoft System.
